roche

Roche’s Tecentriq combo boosts progression-free survival in previously untreated BRAF V600 mutation-positive advanced melanoma

pharmafile | December 16, 2019 | News story | Manufacturing and Production, Research and Development, Sales and Marketing Roche, melanoma, pharma, tecentriq 

Roche has lifted the curtain on new Phase 3 data for its immunotherapy Tecentriq (atezolizumab), confirming that the therapy, when combined with Cotellic (cobimetinib) and Zelboraf (vemurafenib), met its primary endpoint in the treatment of previously untreated BRAF V600 mutation-positive advanced melanoma.

While specifics of the findings were not revealed, Roche confirmed that the combo generated a “significant and clinically meaningful” improvement in progression-free survival (PFS) compared to placebo plus Cotellic and Zelboraf.

The company also confirmed that the full details of the findings would be presented at an upcoming medical meeting, and that they will also help form the basis for regulatory submissions with the FDA and EMA.

“By combining a cancer immunotherapy with targeted therapies, we hope to offer a new approach that improves outcomes for people with advanced, BRAF-mutant melanoma,” commented Dr Levi Garraway, Chief Medical Officer and Head of Global Product Development at Roche. “We look forward to discussing the results with health authorities around the world.”

Advertisement

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Roche secures CE Mark for automated latent tuberculosis blood test

Roche has received CE Mark approval for its Elecsys IGRA TB test, an automated blood …

The Gateway to Local Adoption Series

Latest content